Legislation related to spinal cord injury research and treatment.
2025 · 4th Quarter (Oct 1 - Dec 31)
NERVGEN PHARMA CORP.
Filed by CORNERSTONE GOVERNMENT AFFAIRS, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 7, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CORNERSTONE GOVERNMENT AFFAIRS, INC.
- Client
- NERVGEN PHARMA CORP.
- Filing UUID
- b98cb04c-def9-4028-b0b7-f17dbcfa3cc8
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Legislation related to central nervous system research and therapeutics
Legislation related to spinal cord injury research, therapeutics and approvals
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.